Navigation Links
Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
Date:1/25/2013

TORRANCE, Calif., Jan. 25, 2013 /PRNewswire/ -- Emmaus Life Sciences, Inc., a company dedicated to the discovery, development and commercialization of innovative and cost effective treatments and therapies for rare diseases, today issued the following statement in response to an announcement issued January 24, 2013 by AFH Holding & Advisory, LLC.:

AFH Holding & Advisory and its counsel have misrepresented the nature and effect of a recent ruling by the Los Angeles Superior Court. Far from "preventing [Emmaus] from pursuing a lawsuit it had filed" against AFH Holding & Advisory, the court's decision merely stayed the proceedings in California and held that the claims are contractually required to be brought in Delaware, where Emmaus is currently engaged in litigation against AFH Holding & Advisory and its principal Amir Heshmatpour . The court's narrow and technical ruling in no way addressed the merits of Emmaus's claims, which management believes are strongly supported by the evidence. Neither this nor any further attempt by AFH Holding & Advisory to litigate by press release will dissuade Emmaus from pursuing its claims in whatever forum is appropriate for their adjudication.

About Emmaus Life Sciences
Emmaus is dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases.  

For more information, please visit www.emmauslifesciences.com.

Contacts:

Media: 
Lori Teranishi for Emmaus Life Sciences, Inc. 
415-981-1964
lteranishi@iqprinc.com  

Investors: 
Matt Sheldon for Emmaus Life Sciences, Inc. 
310-279-5975 
msheldon@pondel.com  


'/>"/>
SOURCE Emmaus Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Companys Phase III FDA Sickle Cell Treatment Trials
2. Emmaus Medical Marks Progression of Phase 3 Sickle Cell Disease Clinical Trial During Sickle Cell Awareness Month
3. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
4. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
5. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
6. BioDelivery Sciences Announces Completion of BNX Safety Study
7. Government Hospitals in Ecuador Continue to Invest in Integrity Life Sciences Technology
8. Cumberland Emerging Technologies Expands Life Sciences Center
9. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
10. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
11. BioDelivery Sciences Announces $40 Million Registered Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... -- Endo International plc (NASDAQ: ENDP ) will announce ... of its senior management team will host a conference call and ... The dial-in number to access the call is ... the passcode is 45397076. Please dial in 10 minutes prior to ... A replay of the call will be available from August 8, ...
(Date:7/13/2017)... 13, 2017  New York City-based market research firm Kalorama ... be aware of.  From new products to new costs, to ... a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment ... of the impact the growing population and, to a more ...
(Date:7/11/2017)... WHIPPANY, N.J. , July 11, 2017  Bayer has ... across eight countries as part of its prestigious Bayer Hemophilia ... Children,s Hospital of Philadelphia and Uniformed ... are among the winners. Grant recipients were announced ... Thrombosis and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed in the ... number of hospital acquisitions rose to 23 in the second quarter, up 15% from ... from the 20 announced deals in the year-ago second quarter. Only four of the ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... a $5,000 grant from the C. R. Bard Foundation, Inc. to ... Somerset Hills , a service available through the nonprofit home care agency. Using ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to ... PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network of ... in dermatology, skin cancer , and more. She graduated from the University of ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set of transitions ... timeline. This effect isolates horizontal and vertical lines of pixels and sorts their pixels ... or flipping animation and can be changed using a drop-down menu. Create amazing and ...
(Date:7/20/2017)... Houston, Texas (PRWEB) , ... July 20, 2017 ... ... and litigation law firm headquartered in Houston, is pleased to announce their expansion ... decades of affordable housing experience, directors Alysse Hollis and Ronald Bell, and of ...
Breaking Medicine News(10 mins):